Highest-materiality recent filing
Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 5,209,670.
Acadia Q1 revenue $268M (+10% YoY); DAYBUE sales $101M (+20%); reaffirms guidance
Total Q1 revenues $268M (+10% GAAP YoY, +11% adj); NUPLAZID $167M (+5% GAAP, +6% adj); DAYBUE $101M (+20%).
Acadia R&D Head Elizabeth Thompson plans retirement; stays through 2026 as consultant
Dr. Thompson will retire for personal reasons; remains as Head of R&D until successor appointed, then consultant through end of 2026.
Acadia Pharmaceuticals appoints Jonathan M. Poole to Board of Directors
Poole appointed effective March 3, 2026 as Class II director, term expiring at 2027 annual meeting.
Q4 2025 GAAP total revenue $284M; non-GAAP adjusted $298M (+16% YoY); FY25 GAAP $1.07B, non-GAAP $1.08B.
Acadia Pharmaceuticals reaffirms 2025 net sales guidance above $1B
Anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance.
Acadia Q3 revenue $278.6M (+11% YoY); net income $71.8M; raises FY 2025 guidance
Q3 net product sales: NUPLAZID $177.5M (+12% YoY), DAYBUE $101.1M (+11% YoY).
Director Daniel B. Soland resigns from Acadia board and governance committee chair
Resignation effective October 30, 2025.
Acadia Q2 revenue $264.6M (+9% YoY); NUPLAZID guidance raised to $665-690M
Total revenue $264.6M, NUPLAZID $168.5M (+7%), DAYBUE $96.1M (+14%).
Federal Circuit affirms Acadia's NUPLAZID patent validity in MSN litigation
U.S. Court of Appeals affirmed District Court decision confirming validity of Acadia's '740 composition of matter patent for NUPLAZID (pimavanserin).
Acadia shareholders elect three Class III directors, approve say-on-pay, ratify EY auditor
Elected Catherine Owen Adams, Laura A. Brege, and Elizabeth A. Garofalo, M.D. as Class III directors; each received >129M votes for.
Acadia wins patent litigation for NUPLAZID; court rules for Acadia on infringement and validity
U.S. District Court for Delaware ruled in Acadia's favor in Pimavanserin II Cases regarding '721 formulation patent for NUPLAZID.
Acadia Q1 revenue +19% to $244.3M; net income $19M; ACP-101 results accelerated to Q4 2025
Total Q1 revenue $244.3M, up 19% YoY; NUPLAZID sales $159.7M (+23%), DAYBUE $84.6M (+11%)
Acadia Pharmaceuticals amends bylaws, tightens stockholder nomination and meeting rules
Quorum threshold changed from majority of outstanding shares to majority of voting power.
Acadia Q4 net income $143.7M; FY2024 revenue $957.8M (+32%); guides FY2025 rev $1.03-1.095B
FY2024 total net product sales $957.8M, up 32% YoY; NUPLAZID $609.4M (+11%), DAYBUE $348.4M (+97%).
Acadia sells Rare Pediatric Disease PRV for $150M, one third to partner Neuren
Closed sale of PRV for $150M on Dec 11, 2024, after HSR waiting period expired.
Acadia Pharma terminates COO Brendan Teehan without cause; CEO assumes duties
Brendan Teehan, EVP, COO and Head of Commercial, involuntarily terminated without Cause effective Nov 18, 2024.
Acadia Q3 total revenue $250.4M (+18% YoY); net income $32.8M vs year-ago loss
NUPLAZID sales $159.2M (+10% YoY); DAYBUE sales $91.2M (+36% YoY).
Acadia CEO Stephen R. Davis terminated Sept 23; Catherine Owen Adams appointed
Stephen R. Davis involuntarily terminated without cause as President and CEO effective Sept 23, 2024; resigns from board.
Acadia Q2 total revenue up 46% to $242M; net income $33.4M vs $1.1M last year
NUPLAZID net sales $157.4M (+11% YoY); DAYBUE net sales $84.6M (vs $23.2M YoY).
Acadia shareholders elect directors, approve 2024 equity plan at annual meeting
Julian C. Baker, Stephen R. Biggar, and Daniel B. Soland elected as Class II directors.
Acadia Q1 revenue $205.8M (+74% YoY), net income $16.6M vs loss year ago
NUPLAZID net sales $129.9M (+10% YoY); DAYBUE net sales $75.9M (vs $0 in Q1 2023)
Pimavanserin failed Phase 3 ADVANCE-2 trial for negative symptoms of schizophrenia; primary endpoint not met.
Acadia Pharma Q4 net income $45.8M; 2023 revenue $726.4M (+40%); FY2024 DAYBUE guide $370-420M
Q4 2023 net income $45.8M ($0.28 EPS) vs net loss $41.7M ($0.26 loss) in Q4 2022.
On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) of her planned retirement.
On November 18, 2024, Acadia Pharmaceuticals Inc. (the “Company”) agreed with Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial that he would be involuntarily terminated without Cause (as such term is defined in the Company’s Management Severance Benefit Plan (the “Severance Plan”)) from his position, effective immediately.
Stephen R. Davis is departing the Company and will be succeeded by Catherine Owen Adams.
On September 20, 2024, the Board appointed Catherine Owen Adams, age 54, to serve as the Chief Executive Officer of the Company, including as the “principal executive officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective as of the Transition Date.
Max materiality 0.85 · Median 0.70 · Most common event earnings